Despite the pressing need for new antibiotics in order to avoid a public-health crisis, antibacterial R&D has dwindled seriously in recent years, in part owing to a lack of incentives for companies to make investments in this field. So, the recent passing of an amendment to US legislation that will provide new incentives for antibacterial R&D is to be welcomed.